risperidone / Generic mfg. |
2006-004891-10: Future strategies for vocational rehabilitation schizophrenia |
|
|
| Ongoing | 4 | 100 | Europe | Ziprasidon, Risperidon, Capsule, hard, Film-coated tablet, Zeldox Hartkapseln, Risperdal | Charité - Universitätsmedizin Berlin | The social implications and long-term consequences of mental disorders regarding sick days at work, unemployment rates and early retirement are considerable. This trial is being conducted to understand whether and how atypical antipsychotic treatment effects long-term job rehabilitation in daily life and 2) and whether, how and which social psychiatric strategies (job consulting, vocational services, work rehabilitation, individual cognitive training) support or amplify these beneficial effects. | | | | |
2007-004857-27: Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone |
|
|
| Ongoing | 4 | 50 | Europe | Sertindol, Risperidon, Tablet, Serdolect, Risperdal | Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich | schizophrenic patients (F20.0, F20.1, F20.2, F20.3, F20.5, F20.6, F20.8, F20.9) and healthy controls | | | | |
ChiCTR-TCC-09000584: Study of clinical efficacy and side effects of risperidone in the treatment of schizophrenics |
|
|
| Completed | 4 | 60 | | Risperidone 2-8mg/d, taken once daily for 6 weeks ;Alimentary control for 1-2 days before sampling (low protein, low fat, no eggs, no meat and no milk) | The Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University, Director's research fund | Schizophrenia | | | | |
ChiCTR-TNRC-10001112: The study on clinical and biological characters of bipolar depression and the treatment scheme optimizing |
|
|
| Completed | 4 | 640 | | Lithium, Sodium valproate, Lamotrigine, MECT, Sertraline, Citalopram, Escitalopram, venlafaxine, Quetiapine, Olanzapine, Risperidone, sulpiride | Guangzhou Scientific and Technological Bureau, Guangzhou Board of Health; Guangzhou first people's hospital, The Tackling Key Problems of Guangzhou Scientific and Technological Project | bipolar depressive disorder | | | | |
ChiCTR-RNC-09000522: The genetic association study on individual difference of therapeutic effects of antipsychotic medication |
|
|
| Completed | 4 | 900 | | Risperidone 2-6mg/d; Olanzapine 5-20mg/d; Aripiprazole 10-30mg/d | the Sixth Hospital, Peking University; Ministry of Science and Technology of the People′s Republic of China, Ministry of Science and Technology of the People′s Republic of China | schizophrenia | | | | |
| Completed | 4 | 3000 | | Perphenazine 16-64 mg/d (N=250) or Haloperidol 6-20 mg/d (N=250) ;Risperidone 2-6mg/d ;Olanzapine 5-20 mg/d ;Quetiapine 400-750mg/d ;Aripiperazole 10~30 mg/d ;Ziprasidone 80-160 mg/d | The Sixth Hospital / Institute of Mental Health, Peking University; The Ministry of Science and Technology, The National High Technology Research and Development Program of China (863 program) | Schizophrenia | | | | |
2013-001315-71: Dopaminergic genotype of schizophrenic patients and the benefit of adjunctive aripiprazole to risperidone treatment. The effect on hormonal and metabolic measures Perfil dopaminérgico de los pacientes esquizofrénicos que se beneficiarán de la adición de aripiprazol al tratamiento con risperidona/paliperidona. Efecto sobre parámetros hormonales y metabólicos |
|
|
| Ongoing | 4 | 110 | Europe | Tablet, ABILIFY | Mercedes Zumarraga Ortiz, Fundación Vasca de Investigación Sanitaria (Bioef) | schizophrenia Esquizofrenia, schizophrenia Esquizofrenia, Psychiatry and Psychology [F] - Psychological processes [F02] | | | | |
ChiCTR-RNC-09000521: The genetic association study on individual difference of therapeutic effects of antipsychotic medication |
|
|
| Completed | 4 | 2100 | | Risperidone 2-6mg/d; Olanzapine 5-20mg/d; Qutiapine 400-750mg/d; Ziprasidone 80-160 mg/d; Aripiprazole 10-30mg/d; Clozapine 200-600 mg/d; Perphenazine 20-60 mg/d | Sixth Hospital, Peking University; Ministry of Health, China, Ministry of Health, China. | schizophrenia | | | | |
NCT01458379: Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia |
|
|
| Not yet recruiting | 4 | 50 | US | Paliperidone Palmitate, Risperidone | University of California, Los Angeles, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 10/14 | 12/15 | | |
2014-003651-54: Off-label risperidone in children and adolescents (ORCA): Discontinuation study Off-label risperidon bij kinderen en adolescenten (ORKA): afbouw studie |
|
|
| Ongoing | 4 | 120 | Europe | risperidone, Oral solution | UMCG, ZonMW | no specific condition, we will investigate children who have been using risperidone on an off-label basis for at least one year., no specific condition, we will investigate children who have been using risperidone on an off-label basis for at least one year., Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2004-004482-15: Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung. |
|
|
| Ongoing | 4 | 28 | Europe | Ziprasidon (Zeldox), Risperidon (Risperdal) Tablette, Risperidon (Risperdal) Lösung, Risperidon (Risperdal) Quicklet, Risperidon (Risperdal) Consta, Zeldox, Risperidon (Risperdal), Zeldox, Risperidon (Risperdal) | Universitätsklinikum Aachen, Klinik f. Psychiatrie und Psychotherapie | Patienten mit DSM-IVTR diagnostizierter Schizophrenie | | | | |
2006-005394-22: ESCITALOPRAM MONOTHERAPY COMPARED TO COMBINATION OF ESCITALOPRAM AND RISPERIDONE IN THE TREATMENT OF ACUTE PSYCHOTIC DEPRESSION |
|
|
| Ongoing | 4 | 50 | Europe | Cipralex, Risperdal, Cipralex, Risperdal, Cipralex, Risperdal | Turku university hospital | ICD-10 diagnosis F32.3; psykoottinen masennus, F 33.3; toistuva psykoottinen masennus. | | | | |
2006-007019-25: Pilot open trial of efficacy of Risperidone in Delusional Parasitosis |
|
|
| Ongoing | 4 | 22 | Europe | Risperidone, Risperidone | Barts and the London NHS Trust | Delusional Parasitosis | | | | |
2007-004897-26: Memantine for the Long Term Management of Neuropsychiatric Symptoms in Alzheimer\'s disease - MAIN-AD |
|
|
| Ongoing | 4 | 300 | Europe | Memantine, Risperidone, Ebixa, Risperdal, Zyprexa, Seroquel, Haloperidol (proprietary), Ebixa, Risperdal, Zyprexa, Seroquel, Haloperidol (proprietary) | King\'s College London, North Essex Partnership NHS Foundation Trust | Alzheimer\'s disease | | | | |
2014-003718-10: off-label use of risperidone in people with intellectual disability: A discontinuation study Off-label gebruik van risperidon door mensen met een verstandelijke beperking: een afbouwstudie |
|
|
| Ongoing | 4 | 120 | Europe | Risperidone, | UMCG, ZonMW, Het Zorgondersteuningsfonds | no specific condition, we will investigate people with intellectual disability who have been using risperidone on an off-label basis for at least one year. | | | | |
ChiCTR1900027504: Effect of different dosage of aripiprazole on preventing risperidone-induced hyperprolactinemia: a 8-week, multicenter, randomized, open-label, controlled trial |
|
|
| Completed | 4 | 105 | | Patients treated with risperidone alone for 8 weeks ;Patients treated with risperidone and 5 mg/day aripiprazole for 8 weeks ;Patients treated with risperidone and 10 mg/day aripiprazole for 8 weeks | Shandong Mental Health Center; ShanDong Mental Health Center, Self financing | Schizophrenia | | | | |
2017-002406-12: HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A study comparing continuation versus discontinuation/dose reduction of antipsychotic medication in patients remitted after a first episode of psychosis HAMLETT. Handling Antipsychotic Medication: Lange termijn evaluatie van specifiek toegepaste medicatie. Vergelijking tussen het doorgaan met antipsychotische medicatie bij patiënten die hersteld zijn van eerste psychotische episode en vroegtijdig afbouwen/stoppen. |
|
|
| Not yet recruiting | 4 | 512 | Europe | RISPERIDONE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE, HALOPERIDOL, SULPIRIDE, PALIPERIDONE, PIMOZIDE, LURASIDONE, CLOZAPINE, AMISULPRIDE, TIAPRIDE, SERTINDOLE, CHLORPROTHIXENE, CID5073, CID135398745, CID5002, CID60795, CID3559, CID5355, CID115237, CID16362, CID213046, CID135398737, CID2159, CID5467, CID60149, CID667467, CIS5311507, Tablet, RISPERIDONE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE, HALOPERIDOL, SULPIRIDE, PALIPERIDONE, PIMOZIDE, LURASIDONE, CLOZAPINE, AMISULPRIDE, TIAPRIDE, SERTINDOLE, CHLORPROTHIXENE | University Medical Center Groningen, ZonMw | HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose reduction/discontinuation. HAMLETT vergelijkt de reguliere behandeling van patiënten in remissie na een eerste psychotische episode zoals beschreven in de richtlijnen, namelijk het continueren van antipsychotica voor minstens 1 jaar, met het vroegtijdig afbouwen/stoppen met medicatie., HAMLETT compares continuation versus early discontinuation of antipsychotic medication in patients who have recovered from their first episode of psychosis. HAMLETT vergelijkt de reguliere behandeling van patiënten die hersteld zijn van een eerste psychose, namelijk minimaal 1 jaar antipsychotica gebruiken, met vroegtijdig afbouwen/stoppn met medicatie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 4 | 60 | Europe | DM-Aripiprazole, DM-Olanzapine, DM- Quetiapine, DM-Risperidone, Tablet, Aripiprazole, Olanzapine, Quetiapine, Risperidone | Otsuka Pharmaceutical, Otsuka Pharmaceutical | Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
ChiCTR1800016707: Effects of Four Antipsychotics on Social Cognitive Function and Metabolism in Patients with Stable Schizophrenia |
|
|
| Recruiting | 4 | 275 | | clozapine ;chlorpromazine ;risperidone ;olanzapine ;no | Mental Health Center of Xuhui District Shanghai; Mental Health Center of Xuhui District Shanghai, Shanghai Municipal Commission of Health and Family Planning | schizophrenia | | | | |
ChiCTR1900022365: Tropisetron plus standard care versus placebo to improvement of cognitive impairment for people with schizophrenia: a randomized controlled trial |
|
|
| Not yet recruiting | 4 | 40 | | Tropisetron combined with Risperidone ;Placebo combined with Risperidone | Beijing An'ding Hospital, Capital Medical University; Beijing An'ding Hospital, Capital Medical University, Beijing Municipal Administration of Hospitals'Youth Programme ' Talent cultivation in Beijing Anding Hospital (subject nova) | schizophrenia | | | | |
| Recruiting | 4 | 2000 | | Risperidone ;Olanzapine ;Aripiperazole ;Quetiapine | 国家科技部; Peking University Sixth Hospital, The Ministry of Science and Technology | Schizophrenia | | | | |
2020-005450-18: Can we improve antipsychotic medication safety by measuring medication blood concentration in children and adolescents. |
|
|
| Ongoing | 4 | 140 | Europe | Tablet, Risperidone | Erasmus MC, Erasmus MC | irritability in autism spectrum disorder, Irritability and aggression in children with autism., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003588-85: Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders |
|
|
| Not yet recruiting | 4 | 100 | Europe | Olanzapine, Risperidone, Tablet, , Aripiprazole, Olanzapine, Risperidone | UCLouvain, FNRS | Schizophrenia, schizoaffective disorders,psychosis not otherwise specified, and dellusional disorders, psychosis, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 4 | 400 | RoW | methylphenidate, fluoxetin, risperidone | The Chaim Sheba Medical Center | Velocardiofacial Syndrome, Williams Syndrome, Fragile X Syndrome | 08/24 | 08/24 | | |
NCT04446234: Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building |
|
|
| Not yet recruiting | 4 | 350 | RoW | Risperidone, Aripiprazole, Ziprasidone, Amisulpride, Quetiapine | Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine | Schizophrenia | 12/22 | 12/22 | | |
2022-001582-12: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. Ensayo clínico abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de aripiprazol vs paliperidona / risperidona mediante datos multi-ómicos en pacientes con un primer episodio psicótico. |
|
|
| Ongoing | 4 | 244 | Europe | Injection, Abilify Maintena, Xeplion | Consorcio Centro de Investigacion Biomedica en Red (CIBER), Instituto de Salud Carlos III | First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT03323437: Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia |
|
|
| Completed | 4 | 26 | US | Risperidone | Weill Medical College of Cornell University, New York State Psychiatric Institute, Columbia University, National Institute of Mental Health (NIMH) | Schizophrenia Spectrum and Other Psychotic Disorders | 05/23 | 05/23 | | |
ChiCTR2200066865: The strategy of use, efficacy and safety of Rykindo in the treatment of schizophrenia spectrum disorders:a prospective, single-arm, multicenter real-world study |
|
|
| Recruiting | 4 | 300 | | Long-acting injectable risperidone | Beijing Huilongguan Hospital; Beijing Huilongguan Hospital, Corporate Grants | Schizophrenia spectrum disorders | | | | |
NCT06236451: Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia |
|
|
| Recruiting | 4 | 60 | RoW | Aripiprazole, Risperidone | All India Institute of Medical Sciences, Bhubaneswar | Schizophrenia | 08/25 | 09/25 | | |
| Recruiting | 4 | 140 | Europe | Therapeutic Drug Monitoring, Risperidone plasma level | Erasmus Medical Center, Stichting de Merel, ZonMw: The Netherlands Organisation for Health Research and Development | Autism Spectrum Disorder | 05/24 | 05/24 | | |
CASPAR, NCT04940039: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings |
|
|
| Completed | 4 | 93 | RoW | Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., R092670, Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq., Paliperidone Palmitate 175 mg eq., Paliperidone Palmitate 263 mg eq., Paliperidone Palmitate 350 mg eq., Paliperidone Palmitate 525 mg eq. | Janssen-Cilag International NV | Schizophrenia | 04/24 | 04/24 | | |
NCT04903353: Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole |
|
|
| Recruiting | 4 | 350 | US | Comparison of Risperidone and Aripiprazole | Vanderbilt University Medical Center | Weight Gain, Autism Spectrum Disorder, Medication Side Effect | 07/24 | 07/25 | | |
| Terminated | 4 | 5 | US | Lumateperone, Caplyta, Risperidone, Risperdol | University of New Mexico | Psychosis | 02/24 | 02/24 | | |
SchizOMICS, NCT06060886: Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis |
|
|
| Not yet recruiting | 4 | 244 | NA | Aripiprazole, Paliperidone | Consorcio Centro de Investigación Biomédica en Red (CIBER), Instituto de Salud Carlos III | Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders, Diabetes, NAFLD, Psychosis | 06/25 | 12/25 | | |
| Recruiting | 4 | 524 | US | clozapine, Clozaril, risperidone, Risperdal | University of Texas Southwestern Medical Center, National Institute of Mental Health (NIMH), Beth Israel Deaconess Medical Center, Hartford Hospital, University of Georgia, University of Chicago | Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder | 12/25 | 03/26 | | |
NCT05741502: An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine |
|
|
| Recruiting | 4 | 60 | US | Clozapine, Antipsychotics,Other (non-Clozapine), Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics | Ohio State University | Treatment-resistant Schizophrenia | 03/26 | 06/26 | | |
NCT05737511: Efficacy of Hydroxyzine for Patients With Panic Disorder |
|
|
| Not yet recruiting | 4 | 80 | NA | Hydroxyzine, Atarax, Vistaril, Escitalopram Oxalate, citalopram, fluoxetine, fluvoxamine, paroxetine, paroxetine CR, sertraline, venlafaxine XR,, Alprazolam, clomipramine, clonazepam, diazepam, imipramine, lorazepam, mirtazapine, reboxetine, Bupropion SR, divalproex, duloxetine, gabapentin, levetiracetam, milnacipran, moclobemide, olanzapine, phenelzine, quetiapine, risperidone, tranylcypromine | Sultan Qaboos University | Panic Disorder | 12/26 | 12/26 | | |
NCT04478838: "Extended" (Alternate Day) Antipsychotic Dosing |
|
|
| Recruiting | 4 | 120 | Canada | Risperidone, Risperdal, Olanzapine, Zyprexa, Apo-Olanzapine, Sandoz-Olanzapine, Invega Paliperidone | Centre for Addiction and Mental Health | Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents | 09/27 | 09/28 | | |
2010-021884-34: Relapse prevention in children and adolescents with aggressive anti-social behavior treated with risperidone: a randomized double blind, placebo-controlled, discontinuation study. |
|
|
| Ongoing | 3/4 | 80 | Europe | Risperidone, 6000803, Risperidone, Risperidone | Radboud University Medical Centre Nijmegen, Radboud University, Radboud University Medical Centre Nijmegen, Comisión Europea | Conduct Disorder DSM-IV-TR; 312.8x, APA 2000 | | | | |
2011-000567-26: A randomized double-blind, placebo-controlled study of risperidone in the treatment of aggressive antisocial behavior in youth. |
|
|
| Ongoing | 3/4 | 88 | Europe | Risperidone, 6000803, Risperidone, Risperidone | Radboud University Medical Centre Nijmegen, Radboud University Medical Centre Nijmegen, Comisión Europea | Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000 | | | | |
2008-001015-38: A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia |
|
|
| Ongoing | 3 | 70 | Europe | Risperidone, Rimonabant, Film-coated tablet, Risperidone, Rimonabant | LWL University Hospital Bochum, Ruhr-University Bochum | Schizophrenia | | | | |
2005-002979-33: Estudio de la eficacia y seguridad de risperidona en el tratamiento de adolescentes con esquizofrenia: Estudio abierto de seis meses. |
|
|
| Ongoing | 3 | 8 | Europe | Risperdal 1mg, F5, Risperdal1 mg, Risperdal1 mg | Janssen-Cilag International N.V. | SCHIZOPHRENIA/ Adolescents | | | | |
2008-003623-23: Effect of different antipsychotic medication on craving related brain activity in patients with schizophrenia and cannabis abuse or dependence:a randomized controlled study comparing clozapine and risperidone. |
|
|
| Ongoing | 3 | 70 | Europe | Clozapine, Risperidone, | Academisch medisch centrum, department of psychiatry | A randomized controlled trial comparing the effect of clozapine and risperidone on cannabis craving in cannabis abusing or dependent patients with schizophrenia. Specific cognitive tasks will be used to test craving pathways and associated brain activities are assessed with functional MRI. | | | | |
2009-011594-33: A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia |
|
|
| Ongoing | 3 | 60 | Europe | Risperidone, Tetrabenazine, Risperdal, Risperdal | LWL University Hospital Bochum, Ruhr-University Bochum | Schizophrenia | | | | |
2013-004881-33: Multicentre trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescents Groß an gelegte, einfache offene klinische Studie mit mehreren teilnehmenden Prüfzentren zur Anwendung von Antidepressiva und Neuroleptika (mit /ohne Zulassung) |
|
|
| Ongoing | 3 | 1000 | Europe | Tablet, Abilify, Zyprexa, Leponex, Seroquel, Risperdal, Zeldox, Melneurin, Dipiperon, Saroten, Cipramil, Anafranil, Aponal, Cymbalta, Cipralex, Fluctin, Fevarin, Tofranil, Ludiomil, Remergil, Nortrilen, Paroxat, Zoloft, Stangyl, Trevilor | Universitätsklinikum Würzburg, Kompetenznetz TDM-KJP e.V., BfArM | therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-002859-19: Withdrawing off-label antipsychotics in people with intellectual disabilities: why does it fail? Antipsychotica afbouwen bij mensen met een verstandelijke beperking: waarom lukt het niet? |
|
|
| Ongoing | 3 | 126 | Europe | Risperidone, Pipamperone, Oral liquid, Risperidone, Pipamperone | Erasmus MC, Abrona, Ipse de Bruggen, Amarant | People with challenging behavior and off-label antipsychotic use Mensen met een verstandelijke beperking en gedragsproblemen waarvoor offlabel antipsychotica gebruik, People with challenging behavior and off-label antipsychotic use Mensen met een verstandelijke beperking en gedragsproblemen waarvoor offlabel antipsychotica gebruik, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT05779241: Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 |
|
|
| Completed | 3 | 83 | US | LYN-005, Risperidone, Risperdal | Lyndra Inc. | Schizophrenia, Schizoaffective Disorder | 11/23 | 12/23 | | |
NCT06482554: Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. |
|
|
| Recruiting | 3 | 80 | US | Lumateperone 42 mg, Lumateperone, Risperidone 2 mg, olanzapine; quetiapine; ziprasidone; aripiprazole | Louisiana State University Health Sciences Center Shreveport | Apathy, Schizophrenia, Schizophrenia; Psychosis | 12/26 | 12/26 | | |
2020-006062-36: A Phase II/III, randomized, 4-week, placebo-controlled study, designed to determine the safety, tolerability, and efficacy of evenamide (NW-3509) in patients with chronic schizophrenia. |
|
|
| Ongoing | 2/3 | 196 | Europe, RoW | Evenamide, NW3509, Capsule, hard | Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A, Newron Pharmaceuticals S.p.A., Newron Pharmaceuticals S.p.A | Chronic schizophrenia, Chronic schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2006-004783-31: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of AZD3480 in Schizophrenic Patients on Stable Antipsychotic Monotherapy with quetiapine, risperidone or olanzapine |
|
|
| Ongoing | 2 | 50 | Europe | AZD3480, | AstraZeneca AB | Schizophrenia | | | | |
2020-000094-24: A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia |
|
|
| Ongoing | 2 | 576 | Europe, RoW | Risperidone, MK-8189, Tablet, Capsule, Risperdal (Risperdione) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
CLOZ-AID, NCT04529226: Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis |
|
|
| Active, not recruiting | 2 | 75 | Europe | Clozapine, Nemex, Leponex, haloperidol, pimozide, olanzapine, risperidone, amisulpride | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Psychosis, Intellectual Disability | 01/25 | 12/25 | | |
| Completed | 2 | 500 | Europe, Japan, US, RoW | MK-8189, Risperidone, Placebo to MK-8189, Placebo to risperidone | Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Schizophrenia | 06/24 | 06/24 | | |
SYNVEST, NCT06512220: Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression |
|
|
| Not yet recruiting | 2 | 12 | Canada | Psilocybin 25 mg, PEX010, Risperidone 1 MG, MAR-Risperidone | Centre for Addiction and Mental Health | Treatment Resistant Depression | 08/26 | 08/26 | | |
NCT04105231: Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use |
|
|
| Recruiting | 2 | 130 | Europe | Cannabidiol, Epidiolex, Risperidone, Risperidon | Lone Baandrup, Danish Center for Sleep Medicine, Copenhagen University Hospital, Denmark, Glostrup University Hospital, Copenhagen, University of Copenhagen | Dual Diagnosis | 12/24 | 06/25 | | |
| Recruiting | 2 | 60 | Canada | Psilocybin 25 mg, Risperidone 1 MG, Placebo | Centre for Addiction and Mental Health | Treatment-resistant Depression | 02/26 | 02/26 | | |
OCD-RT, NCT05401019: Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD) |
|
|
| Withdrawn | 2 | 52 | NA | Pramipexole, Risperidone | Clinical Academic Center (2CA-Braga), University of Minho | Obsessive-Compulsive Disorder | 12/26 | 12/26 | | |
ACTRN12619001569190: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Risperidone Extended Release Capsules in Patients with Schizophrenia, Schizoaffective Disorder or Bipolar 1 Disorder |
|
|
| Not yet recruiting | 1 | 8 | | | Lyndra Australia Pty Ltd, Lyndra Australia Pty Ltd | Schizophrenia, Schizoaffective disorder, Bipolar 1 disorder | | | | |
| Completed | 1 | 44 | | Oral 2mg the test tablets ;Oral 2mg the control tablets | First Affiliated Hospital, College of Medicine, Zhejiang University; Zhejang Huahai Pharmaceutical Co., Ltd., China, Zhejang Huahai Pharmaceutical Co.,Ltd., (China ); Department of Education of Zhejiang | psychoses | | | | |
ChiCTR-IPR-15006764: Comparative bioavailability of dispersible and conventional tablets of risperidone: a randomized, open-label, two-period crossover study in healthy male Chinese volunteers |
|
|
| Not yet recruiting | 1 | 48 | | The volunteers was given 1 mg*2 Risperidone dispersible tablets in first cycle, and 1 mg*2 Risperidone tablets in second cycle. ;The volunteers was given 1 mg*2 Risperidone tablets in first cycle , and 1 mg*2 Risperidone dispersible tablets in second cycle. ;The volunteers was given 1 mg*2 Risperidone dispersible tablets after breakfast in first cycle , and 1 mg*2 Risperidone tablets after breakfast in second cycle. ;The volunteers was given 1 mg*2 Risperidone tablets after breakfast in first cycle , and 1 mg*2 Risperidone dispersible tablets after breakfast in second cycle. | The first affiliated hospital, School of Medicine, Zhejiang University; Level of the institution:, Wanbangde Pharmaceutical Group Co., Ltd | schizophrenia | | | | |
| Recruiting | 1 | 40 | | Phase I: JMP-Risperidone produced Risperdal Tab 4 mg ;Phase I: Janssen-Cilag SpA-V.C.Janssen produced Risperdal Tab 4 mg ;Phase II: Janssen-Cilag SpA-V.C.Janssen produced Risperdal Tab 4 mg ;Phase II: JMP-Risperidone produced Risperdal Tab 4 mg | Institute of Clinical Pharmacy, Central South University; Jean-Marie Pharmacal Co. Ltd., Hong Kong, Jean-Marie Pharmacal Co. Ltd., Hong Kong | Pharmacokinetics and Bioequivalence Study in human | | | | |
ChiCTR-IIR-17014142: A Single-Dose, Randomized, Open-Label, Two-Treatment, Two-Period, Two-Cohort, Crossover Study to Assess the Bioequivalence of Xian Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects Compared with Gurabo Risperdal Tablets |
|
|
| Recruiting | 1 | 72 | | T-R ;R-T ;T-R ;R-T | Beijing Shijitan Hospital Capital Medical University; Xian-Janssen Pharmaceutical Ltd, Xian-Janssen Pharmaceutical Ltd | Metal Disease | | | | |
ChiCTR1900024422: The mutual promotion between family intervention and rTMS therapy improve cognitive function and negative symptoms in patients with schizophrenia |
|
|
| Recruiting | 1 | 400 | | Risperidone ;Risperidone+rTMS ;Risperidone+rTMS+family intervention ;Risperidone+family intervention | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, National Natural Science Foundation of China | schizophrenia | | | | |
NCT05491720: Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder |
|
|
| Completed | 1 | 45 | RoW | RisperiDONE 1 MG/ML, transcranial direct current stimulation, tDCS, Placebo, sham transcranial direct current stimulation | The National Brain Mapping Laboratory (NBML), Ardabil University of Medical Sciences, Leibniz Research Centre for Working Environment and Human Factors, University of Tehran | Autism Spectrum Disorder | 03/22 | 08/22 | | |
NCT05402111: A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard |
|
|
| Completed | 1 | 31 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 09/23 | 09/23 | | |
QUARTZ, NCT06276361: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia |
|
|
| Recruiting | 1 | 100 | RoW | Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Deltoids | Rovi Pharmaceuticals Laboratories | Schizophrenia | 05/26 | 05/26 | | |
NCT05542264: A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia |
|
|
| Completed | 1 | 19 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 02/24 | 02/24 | | |
| Recruiting | 1 | 12 | Europe | Risperidone oral solution, Twinings English Breakfast tea, Pepsi Max beverage | Helsinki University Central Hospital, University of Helsinki | Psychosis, Food-drug Interaction | 12/24 | 12/24 | | |
tDCS&ASD, NCT06368726: Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders |
|
|
| Enrolling by invitation | 1 | 180 | Europe | tDCS or Transcranial Direct Current Stimulation, tES Transcranial Electrical Stimulation, Risperidone, Diet, educational or speech therapies, pictographs | Spanish Foundation for Neurometrics Development, Fundacion para la Salud Materno Infantil | Attention, Visual Perceptual Weakness, Social Behavior, Fluency Disorder, EEG With Periodic Abnormalities | 05/25 | 07/25 | | |
NCT04071639: Symptomatic Therapy for Patients With Huntington's Disease |
|
|
| Recruiting | 1 | 60 | RoW | Haloperidol 2Mg Tab, Haloperidol Tables, H31021234, Risperidone 1Mg Tab, Risperidone, H20010309, Zoloft 50Mg Tablet, Sertraline Hydrochloride Tablets, H10980141, Idebenone, Idebenone,H10970363, Deutetrabenazine Oral Tablet [Austedo], Deutetrabenazine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Huntington Disease | 12/24 | 12/24 | | |
ChiCTR-TRC-13003145: Anti-toxoplasma Chinese Medicine as an Adjunct Therapy in Schizophrenia with seropositivity to T. gondii |
|
|
| Completed | N/A | 100 | | artemether and risperidone ;Placebo and risperidone | Renmin Hospital of Wuhan University; Renmin Hospital of Wuhan University, the Stanley Medical Research Institute (USA) | schizophrenia | | | | |
ChiCTR-TRC-14004186: Research of the variance on patients with schizophrenia treated with aripiprazole on hyperprolactinemia induced by risperidone or paliperidone |
|
|
| Completed | N/A | 60 | | adjunctive with 5mg aripiprazole ;single risperidone treatment | Shanghai Mental Health Center; Level of the institution:, project of Shanghai Mental Health Center | Schizophrenia | | | | |
ChiCTR-IOR-15006278: Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial |
|
|
| Completed | N/A | 113 | | no additional treatment ;adjunctive treatment with aripiprazole 10mg/day | The Second Affiliated Hospital/ Xinxiang Medical University; The Second Affiliated Hospital/ Xinxiang Medical University, Funding for this study was provided by the National Natural Science Foundation of China (No.30971058; No.81071090, 81371472), the Natural Science Foundation of Henan (No.102300413208) | Schizophrenia | | | | |
ChiCTR-IOR-14005304: A randomized, 13-week study assessing the efficacy and safety of paliperidone palmitate and olanzapine in first-episode schizophrenic patients |
|
|
| Recruiting | N/A | 100 | | Palm trees risperidone long-acting injection Paley ;Control | First Affiliated Hospital, College of Medicine, Zhejiang University; First Affiliated Hospital, College of Medicine, Zh, National Natural Science Foundation (81301158) | Schizophrenic | | | | |
ChiCTR-POC-15006642: Follow-up study of the risk of relapse and the function after reducing high doses risperidone maintenance treatment in patient with schizophrenia |
|
|
| Not yet recruiting | N/A | 100 | | risperidone dose reduced by 50% and then maintained ;risperidone dose kept constant | Guangzhou Brain Hospital (Guangzhou Huiai Hospital, The Affiliated Brain Hospital of Guangzhou Medical University); Guangzhou Brain Hospital (Guangzhou Huiai Hospital, The Affiliated Brain Hospital of Guangzhou Medical University), Guangzhou Municipal Health Bureau | schizophrenia | | | | |
ChiCTR1800014844: The effect of antipsychotic on first-onset drug-naive schizophrenia: brain image, DNA methylation and gene expression study |
|
|
| Completed | N/A | 80 | | Risperidone ;No | The Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University, National Natural Science Foundation of China | Schizophrenia | | | | |
ChiCTR-ONN-17012021: The effect and mechanism of Ditan Huayu therapy in treating paranoid schizophrenia based on histogenous hypoxia |
|
|
| Not yet recruiting | N/A | 120 | | oral risperidone ;risperidone combined Ditan Huayu Therapy ;none | The Affiliated Brain Hospital of Guangzhou Medical University(Guangzhou Huiai Hospital); The Affiliated Brain Hospital of Guangzhou Medical University(Guangzhou Huiai Hospital), Guangdong Province Administration of Traditional Chinese Medicine (program number: 20171209) and Guangzhou Huiai Hospital | paranoid schizophrenia | | | | |
ChiCTR-IOR-16009579: The multi-dimensional evaluation of the individualized treatment of atypical antipsychotics |
|
|
| Not yet recruiting | N/A | 800 | | Olanzapine ;Risperidone ;Aripiprazole ;Amisulpride | Shanghai Mental Health Center; Shanghai Mental Health Center, The project to promote the municipal hospital clinical skills and innovation action for three year | schizophrenia | | | | |
ChiCTR1800016687: Research on the therapeutic effect and safety of electropuncture on metabolic syndrome due to olanzapine and risperidone |
|
|
| Recruiting | N/A | 30 | | electropuncture ;shame electropuncture | Beijing Anding Hospital affiliated to Capital Medical University; Beijing Anding Hospital affiliated to Capital Medical University, Capital Medical University | Capital Medical University | | | | |
ChiCTR1900023058: The effects of celecoxib plus risperidone on psychopathology, cognition and cytokine levels in chronic schizophrenia: a prospective, randomized, controlled clinical trial. |
|
|
| Recruiting | N/A | 90 | | Risperidone4~6mg/d ;Risperidone 4~6mg/d, Celecoxib 200mg/d ;Risperidone 4~6mg/d, Celecoxib 400mg/d | Jingzhou Mental Hospital; Jingzhou Mental Hospital, Hospital Research Fund | schizophrenia | | | | |
ChiCTR1900027767: Efficacy and safety of adjunctive low-concentration sevoflurane for the treatment of hospitalized acute schizophrenia: a multicenter, randomized, active-controlled clinical trial. |
|
|
| Recruiting | N/A | 50 | | antipsychotics (Risperidone/Paliperidone/Olanzapine) and Sevoflurane ;antipsychotics (Risperidone/Paliperidone/Olanzapine) | Guangzhou Women and Children's Medical Center; Guangzhou Women and Children's Medical Center, National Natural Science Foundation of China (81671116 and 81870823) | schizophrenia | | | | |
ChiCTR2100041857: Repetitive transcranial magnetic stimulation (rTMS) treatment for risperidone-induced hyperprolactinemia: a randomized controlled study |
|
|
| Completed | N/A | 55 | | rTMS ;pseudo rTMS | Fuzhou Neuropsychiatric Hospital Affiliated to Fujian Medical University; Fuzhou Neuropsychiatric Hospital Affiliated to Fujian Medical University, Self-raised | Hyperprolactinemia | | | | |
NCT06200584: Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics |
|
|
| Completed | N/A | 140 | RoW | Risperidone, neuroleptics, Olanzapine, Quetiapine, Risperidone and Vitamin D and Vitamin E, vitamin, Olanzapine and Vitamin D and Vitamin E, Quetiapine and Vitamin D and Vitamin E | Dr Rabia Arshad | Antipsychotics and Neuroleptics Toxicity | 06/21 | 06/21 | | |
SWITCH, NCT04312503: Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia" |
|
|
| Completed | N/A | 95 | Europe | Lurasidone, Latuda, aripiprazole, olanzapine, quetiapine or risperidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | Schizophrenia | 10/22 | 10/22 | | |
NCT02822092: Striatal Connectivity and Clinical Outcome in Psychosis |
|
|
| Completed | N/A | 196 | US | Risperidone or Aripiprazole (patients only), Risperidal, Aripiprazole | Northwell Health, National Institutes of Health (NIH) | Psychotic Disorders | 12/23 | 12/23 | | |
NCT06128408: The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset |
|
|
| Not yet recruiting | N/A | 300 | NA | risperidone, olanzapine, aripiprazole | Peking University | Treatment-resistant Schizophrenia | 10/24 | 10/24 | | |
ChiCTR2200059183: Mechanism and application of intestinal flora regulating TLR4 / NF KB pathway on the anti schizophrenic effect of risperidone |
|
|
| Not yet recruiting | N/A | 100 | | None | Wuxi Mental Health Center; Wuxi Mental Health Center, Wuxi Health Commission | Major depression disorder | | | | |
| Completed | N/A | 509 | US | Risperidone, Risperdal, Aripiprazole, Abilify | Duke University, The Emmes Company, LLC | Weight, Body | 11/23 | 11/23 | | |
NCT05833399: Correlation of Genetic Variations With Clinical Response in Substance Use Disorder |
|
|
| Recruiting | N/A | 200 | RoW | Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone, Seroquel, Olapex, Remeron, Tegretol, Moodapex, Tryptizol, Neurazine and Apexidone. | Alexandria University | Substance Use Disorders, Substance Dependence | 03/24 | 12/24 | | |
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) |
|
|
| Recruiting | N/A | 5000 | Canada, US | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome | 09/26 | 09/27 | | |
versus, NCT05868720: EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL |
|
|
| Not yet recruiting | N/A | 42 | NA | Risperidone, Aripiprazole | All India Institute of Medical Sciences, Bhubaneswar | The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level | 05/24 | 03/25 | | |
NCT06581302: Magnetic Seizure Therapy for Psychotic Disorders |
|
|
| Not yet recruiting | N/A | 50 | RoW | Magnetic seizure therapy by Magnetic stimulator, Seizure therapy, Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc), antipsychotics | Shanghai Jiao Tong University School of Medicine | Psychotic Disorders | 12/25 | 12/25 | | |
ChiCTR2100048395: Effect of ruprasidone on the clinical efficacy and serum BDNF level of early risperidone in the treatment of unresponsive first-episode schizophrenia |
|
|
| Not yet recruiting | N/A | 200 | | Risperidone ;Early dressing change ;Cozapine | Huzhou Third People's Hospital; Huzhou Third People's Hospital, Huzhou Third People's Hospital | Schizophrenia | | | | |
NCT05473741: Risk of Breakthrough Symptoms With Long-Acting Injectable Medications |
|
|
| Recruiting | N/A | 180 | Canada | Second Generation Long-Acting Injectable Antipsychotic Medications, paliperidone palmitate, risperidone, aripiprazole | Centre for Addiction and Mental Health, Janssen Inc. | Schizophrenia, Schizophrenia Relapse | 12/25 | 12/25 | | |
ChiCTR2400087635: Exploring the biomarkers and biotypes related to objective diagnosis and treatment of schizophrenia based on the multi-dimensional-data partition |
|
|
| Not yet recruiting | N/A | 1000 | | According to the recommendations in the "Guidelines for the Prevention and Treatment of Schizophrenia," the present study will use first-line antipsychotic medications: risperidone, olanzapine, or aripiprazole as monotherapy. The equivalent dose is chlorpromazine (600-700 mg/day). It is required that the medication be titrated to an effective equivalent therapeutic dose within two weeks after the baseline assessment.; Not applicable | Peking University Sixth Hospital; Peking University Sixth Hospital, National Key R&D Programs - China Innovation Funding (Project number: 2023YFE0119400) | Schizophrenia | | | | |
| Recruiting | N/A | 600 | | Risperidone ;None | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, The National Natural Science Foundation of China | schizophrenia (SCZ) | | | | |
ChiCTR2400081375: The development and application of diagnosis and treatment technology for adolescent emotional and behavioral disorders |
|
|
| Not yet recruiting | N/A | 1760 | | Selecte one of the three antipsychotic drugs for treatment: risperidone, aripiprazole and olanzapine; Selecte a single antidepressant of SSRI for treatment; Selecte one of the three mood stabilizers for treatment: risperidone, aripiprazole and olanzapine; none; none; Common rTMS treatment; Image navigation accurate rTMS treatment | He'nan Mental Hosptial; He'nan Mental Hosptial, He'nan Provincial Science and Technology Department | Adolescent emotional and behavioral disorders(Schizophrenia, Depression, Bipolar disorder) | | | | |